Comparative Pharmacology
Head-to-head clinical analysis: FORTESTA versus TESTRED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORTESTA versus TESTRED.
FORTESTA vs TESTRED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone replacement therapy; testosterone binds to and activates androgen receptors, influencing gene transcription and protein synthesis, leading to the development of male secondary sex characteristics and maintenance of libido, muscle mass, and bone density.
Testosterone is an androgen receptor agonist, promoting development of male secondary sexual characteristics and anabolic effects.
Apply one 30 mg metered-dose transdermal system to abdomen or upper arm once daily at the same time each day.
Testosterone enanthate 200 mg intramuscularly every 2 weeks.
None Documented
None Documented
Terminal elimination half-life is 3–4 hours; not clinically significant for once-daily transdermal administration due to sustained absorption.
Terminal elimination half-life for testosterone is 2-4 hours; testosterone enanthate has a half-life of 4-5 days due to slow release from the oily depot. Clinical context: shorter half-life requires more frequent dosing for stable serum levels.
Primarily renal (90% as glucuronide and sulfate conjugates, 10% unchanged); approximately 1% fecal.
Approximately 90% of administered testosterone is excreted in urine as glucuronide and sulfate conjugates of testosterone and its metabolites (androsterone, etiocholanolone). About 6% is excreted in feces via bile. Unchanged testosterone excretion is negligible (<1%).
Category C
Category C
Androgen
Androgen